Cargando…

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators

The structure of the Fab region of antibodies is critical to their function. By introducing single cysteine substitutions into various positions of the heavy and light chains of the Fab region of trastuzumab, a potent antagonist of HER2, and using thiol chemistry to link the different Fabs together,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheer, Justin M., Sandoval, Wendy, Elliott, J. Michael, Shao, Lily, Luis, Elizabeth, Lewin-Koh, Sock-Cheng, Schaefer, Gabriele, Vandlen, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527469/ https://www.ncbi.nlm.nih.gov/pubmed/23284778 http://dx.doi.org/10.1371/journal.pone.0051817

Ejemplares similares

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Real-time observation of epitaxial graphene domain reorientation
por: Rogge, Paul C., et al.
Publicado: (2015)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Research reorientation
por: Chander, N. Gopi
Publicado: (2016)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan, Dongyu, et al.
Publicado: (2018)

Site-Specific (68)Ga Radiolabeling of Trastuzumab Fab via Methionine for ImmunoPET Imaging
por: Yue, Thomas T. C., et al.
Publicado: (2023)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

A Reorientation in Psychotherapy
por: Tendler, A. D.
Publicado: (1933)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Single chain Fab (scFab) fragment
por: Hust, Michael, et al.
Publicado: (2007)

Spatial Reorientation by Geometry in Bumblebees
por: Sovrano, Valeria Anna, et al.
Publicado: (2012)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

A comparison of (111)In- or (64)Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
por: Chan, Conrad, et al.
Publicado: (2011)

An antibody with Fab-constant domains exchanged for a pair of C(H)3 domains
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2018)

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations
por: Ramos, Javier, et al.
Publicado: (2019)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
por: Kuchukulla, Ratnakar Reddy, et al.
Publicado: (2022)

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
por: Liu, Xinlin, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

AZD9773 is a novel and potent anti-TNFα polyclonal ovine immune Fab
por: Newham, P, et al.
Publicado: (2011)

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy
por: Bai, Xuefei, et al.
Publicado: (2021)

Structural mechanism of Fab domain dissociation as a measure of interface stability
por: Pomarici, Nancy D., et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

A Plan for the Reorientation of the Social Services
por: Young, J. Campbell
Publicado: (1937)

Olfaction, valuation, and action: reorienting perception
por: Castro, Jason B., et al.
Publicado: (2014)

Cell reorientation under cyclic stretching
por: Livne, Ariel, et al.
Publicado: (2014)

Covid-19 and Quad’s “Soft” Reorientation
por: Upadhyay, Shreya
Publicado: (2021)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Production of single chain Fab (scFab) fragments in Bacillus megaterium
por: Jordan, Eva, et al.
Publicado: (2007)

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain
por: Fenn, Sebastian, et al.
Publicado: (2013)

Comparing domain interactions within antibody Fabs with kappa and lambda light chains
por: Toughiri, Raheleh, et al.
Publicado: (2016)

Site-Specific Antibody–Drug Conjugates in Triple Variable Domain Fab Format
por: Hwang, Dobeen, et al.
Publicado: (2020)

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
por: Benedetti, Filippo, et al.
Publicado: (2021)

HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
por: Zhou, Yihan
Publicado: (2023)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fstujouavudb85utgjhu430ccs